High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections

Chan,Ray Chun-Fai; Leung,Richard  H.; Posadas,Albert; Lorey,Thomas   S.; Shaw,Allison  J.

doi:10.3892/br.2018.1047

High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections

Authors:
- Ray Chun-Fai Chan
- Richard H. Leung
- Albert Posadas
- Thomas S. Lorey
- Allison J. Shaw
View Affiliations

Affiliations: Department of Flow Cytometry, Kaiser Permanente Regional Laboratory Northern California, The Permanente Medical Group, Inc., Berkeley, CA 94710, USA
Published online on: January 24, 2018 https://doi.org/10.3892/br.2018.1047
Pages: 224-234
Copyright: © Chan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flow cytometry is the gold standard in diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) by detecting the absence of glycol-phosphatidyl inositol (GPI)‑linked protein expression on granulocyte and monocyte surfaces. However, the current assays are not optimized and require improvement, particularly in reducing background fluorescence and optimizing sensitivity and specificity. With more fluorochromes available and with advances in instrument engineering, rare populations may be identified with high sensitivity. The present study assessed an 8-color combination of comprehensive GPI-linked markers, namely fluorescein-labeled proaerolysin (FLAER), cluster of differentiation 157 (CD157), CD24 and CD14, and the lineage markers for granulocyte (CD15) and monocyte (CD64) cells to detect PNH clones. Additionally, to optimize the PNH flow assay, a ‘dump’ channel was used, comprised of CD5 and CD19, to exclude non-specific binding in order to reduce background. This method aimed to improve sensitivity and reduce the background to create an optimized PNH flow cocktail. The results demonstrated that the current 4-color PNH combination identifies a CD55- and FLAER+ population that is not PNH clones. By contrast, the 8-color panel delineated PNH clones from both monocyte and granulocytes by using granulocyte antigen (CD15) and monocyte antigen (CD64) as a gating strategy. The sensitivity was 0.01% for granulocytes and 0.05% for monocytes with an acquisition of 100,000 monocyte and granulocyte events. The background on a normal whole blood sample was 0.00076% on monocytes and 0.00277% on granulocytes. Thus, overall, the 8-color PNH assay exhibited high levels of specificity and sensitivity. The 8-color combination facilitated the improvement and enhancement of sensitivity in PNH clone identification, and may provide a useful tool for pathologists in PNH diagnosis and for monitoring patients at risk of developing classical/hemolytic PNH, to enable treatment to be delivered promptly.

View Figures

View References

1	Chattopadhyay PK, Perfetto SP and Roederer M: The colorful future of cell analysis by flow cytometry. Discov Med. 4:255–262. 2004.PubMed/NCBI
2	Chan RC, Kotner JS, Chuang CM and Gaur A: Stabilization of pre-optimized multicolor antibody cocktails for flow cytometry applications. Cytometry B Clin Cytom. 92:508–524. 2017. View Article : Google Scholar : PubMed/NCBI
3	Hill A, Platts PJ, Smith A, Richards SJ, Cullen MJ, Hill QA, Roman E and Hillmen P: The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 108:9852006.
4	Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, et al International PNH Interest Group, : Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 106:3699–3709. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hosokawa K, Kajigaya S, Keyvanfar K, Qiao W, Xie Y, Townsley DM, Feng X and Young NS: T Cell transcriptomes from paroxysmal nocturnal hemoglobinuria patients reveal novel signaling pathways. J Immunol. 199:477–488. 2017. View Article : Google Scholar : PubMed/NCBI
6	Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P, Gallagher S, Smith GP, Richards SJ, White J, et al: Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: A new approach to PNH therapy. Blood. 107:2131–2137. 2006. View Article : Google Scholar : PubMed/NCBI
7	Al-Ani F, Chin-Yee I and Lazo-Langner A: Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: Patient selection and special considerations. Ther Clin Risk Manag. 12:1161–1170. 2016. View Article : Google Scholar : PubMed/NCBI
8	Fletcher M, Whitby L, Whitby A and Barnett D: Current international flow cytometric practices for the detection and monitoring of paroxysmal nocturnal haemoglobinuria clones: A UK NEQAS survey. Cytometry B Clin Cytom. 92:266–274. 2017. View Article : Google Scholar : PubMed/NCBI
9	Hill A, DeZern AE, Kinoshita T and Brodsky RA: Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 3:170282017. View Article : Google Scholar : PubMed/NCBI
10	Brodsky RA: Paroxysmal nocturnal hemoglobinuria. Blood. 124:2804–2811. 2014. View Article : Google Scholar : PubMed/NCBI
11	Nafa K, Bessler M, Castro-Malaspina H, Jhanwar S and Luzzatto L: The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis. 24:370–384. 1998. View Article : Google Scholar : PubMed/NCBI
12	Canalejo K, Riera Cervantes N, Felippo M, Sarandría C and Aixalá M: Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period. Int J Lab Hematol. 36:213–221. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, et al: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 323:1184–1189. 1990. View Article : Google Scholar : PubMed/NCBI
14	Motoyama N, Okada N, Yamashina M and Okada H: Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol. 22:2669–2673. 1992. View Article : Google Scholar : PubMed/NCBI
15	Rother RP, Bell L, Hillmen P and Gladwin MT: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA. 293:1653–1662. 2005. View Article : Google Scholar : PubMed/NCBI
16	Hill A, Richards SJ and Hillmen P: Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 137:181–192. 2007. View Article : Google Scholar : PubMed/NCBI
17	van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J and von dem Borne AE: Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood. 76:1853–1859. 1990.PubMed/NCBI
18	Hall SE and Rosse WF: The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 87:5332–5340. 1996.PubMed/NCBI
19	Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT and Borowitz MJ: Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 114:459–466. 2000. View Article : Google Scholar : PubMed/NCBI
20	Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT and Richards SJ; Clinical Cytometry Society, : Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 78:211–230. 2010.PubMed/NCBI
21	Movalia M and Illingworth A: Distribution of PNH clone sizes within high risk diagnostic categories among 481 PNH positive patients identified by high sensitivity flow cytometry. Blood. 120:12712012.
22	Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, et al: Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 162:62–73. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, Mizoguchi H, Omine M and Nakao S: Minor population of CD55CD59 blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 107:1308–1314. 2006. View Article : Google Scholar : PubMed/NCBI
24	Hillmen P, Lewis SM, Bessler M, Luzzatto L and Dacie JV: Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 333:1253–1258. 1995. View Article : Google Scholar : PubMed/NCBI
25	Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM and Hillmen P: Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood. 117:6786–6792. 2011. View Article : Google Scholar : PubMed/NCBI
26	Sutherland DR, Acton E, Keeney M, Davis BH and Illingworth A: Use of CD157 in FLAER-based assays for high-sensitivity PNH granulocyte and PNH monocyte detection. Cytometry B Clin Cytom. 86:44–55. 2014. View Article : Google Scholar : PubMed/NCBI
27	Gatti A, Del Vecchio L, Geuna M, Della Porta MG and Brando B: Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. Eur J Haematol. 99:27–35. 2017. View Article : Google Scholar : PubMed/NCBI
28	Marinov I, Illingworth AJ, Benko M and Sutherland DR: Performance characteristics of a non-fluorescent aerolysin-based paroxysmal nocturnal hemoglobinuria (PNH) assay for simultaneous evaluation of PNH neutrophils and PNH monocytes by flow cytometry, following published PNH guidelines. Cytometry B Clin Cytom. Jun 13–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
29	Kusenda J, Fajtova M and Kovarikova A: Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry. Neoplasma. 61:119–127. 2014. View Article : Google Scholar : PubMed/NCBI
30	Edwards BS, Oprea T, Prossnitz ER and Sklar LA: Flow cytometry for high-throughput, high-content screening. Curr Opin Chem Biol. 8:392–398. 2004. View Article : Google Scholar : PubMed/NCBI
31	Sutherland DR, Keeney M and Illingworth A: Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B Clin Cytom. 82:195–208. 2012. View Article : Google Scholar : PubMed/NCBI
32	Hernández-Campo PM, Almeida J, Sánchez ML, Malvezzi M and Orfao A: Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: A frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom. 70:71–81. 2006. View Article : Google Scholar : PubMed/NCBI
33	Seifert RP, Bulkeley W III, Zhang L, Menes M and Bui MM: A practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia. Ann Diagn Pathol. 18:253–260. 2014. View Article : Google Scholar : PubMed/NCBI
34	Mayson E, Saverimuttu J and Cartwright K: CD5-positive follicular lymphoma: Prognostic significance of this aberrant marker? Intern Med J. 44:417–422. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pati HP and Jain S: Flow cytometry in hematological disorders. Indian J Pediatr. 80:772–778. 2013. View Article : Google Scholar : PubMed/NCBI
36	Krause DS, Delelys ME and Preffer FI: Flow cytometry for hematopoietic cells. Methods Mol Biol. 1109:23–46. 2014. View Article : Google Scholar : PubMed/NCBI
37	Huh YO and Ibrahim S: Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease. Hematol Oncol Clin North Am. 14:1251–1265. 2000. View Article : Google Scholar : PubMed/NCBI
38	Chung NG, Buxhofer-Ausch V and Radich JP: The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens. 68:371–385. 2006. View Article : Google Scholar : PubMed/NCBI
39	Rawstron AC: Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program. 430–439. 2009. View Article : Google Scholar : PubMed/NCBI
40	Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, et al: Central nervous system involvement in adult acute lymphoblastic leukemia: Diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis. 6:e20140752014. View Article : Google Scholar : PubMed/NCBI
41	Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-Céligny P, Juweid M and Guermazi A: Follicular non-Hodgkin's lymphoma. Clin Radiol. 65:408–420. 2010. View Article : Google Scholar : PubMed/NCBI
42	Narita A, Muramatsu H, Okuno Y, Sekiya Y, Suzuki K, Hamada M, Kataoka S, Ichikawa D, Taniguchi R, Murakami N, et al: Development of clinical paroxysmal nocturnal haemoglobinuria in children with aplastic anaemia. Br J Haematol. 178:954–958. 2017. View Article : Google Scholar : PubMed/NCBI
43	Timeus F, Crescenzio N, Longoni D, Doria A, Foglia L, Pagliano S, Vallero S, Decimi V, Svahn J, Palumbo G, et al: Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: A multicentre study. PLoS One. 9:e1019482014. View Article : Google Scholar : PubMed/NCBI